News Center

Home page

Peak Report

News reports

China's First Expert Consensus on Clinical Drug Treatment of Osteoarthritis Releases Key Products of Peak Pharmaceutical Yueyining Selected

Release time:

2021-07-21

News from our newspaper # February 10 , the Sports Medical Branch of the Chinese Medical Association and other units jointly released the "Expert Consensus on Clinical Drug Treatment of Osteoarthritis" in Hangzhou. This is the first time that the Chinese medical community has released osteoarthritis. Related expert consensus. Peak Pharmaceuticals' key product, Yue Yining (Aceclofenac Sustained Release Tablets), is included in the consensus list of therapeutic drugs.

"Expert Consensus on Clinical Drug Treatment of Osteoarthritis" was initiated by Chen Shiyi, winner of the "Chinese Medicine Award", director of the Sports Medicine Center of Fudan University, and director of the Orthopedic Arthroscopic Diagnosis and Treatment Technology Training Base of the Ministry of Health (Shanghai), the sports medicine branch of the Chinese medical association, the sports medicine group of the orthopaedic branch of the Chinese medical association, the arthroscopic society of the orthopaedic branch of the Chinese medical association and other units organized more than 30 relevant experts to jointly compile it, which took nearly 1 years to complete. the consensus is divided into 6 parts, and the full text is nearly 2 words. The experts participating in the discussion are distributed in 27 large-scale tertiary hospitals in 16 provinces (cities, autonomous regions) across the country, involving multiple disciplines such as orthopedics, sports medicine, pain, pharmacy, and evidence-based medicine. The formulation principles of rigorous, standardized, objective, practical, and economical, adhere to the guidance of evidence-based medicine, and fully integrate the current clinical practice of osteoarthritis in China, give more than 20 best clinical medication plan.

Yueyining (Aceclofenac Sustained Release Tablets), a key product of Jianfeng Pharmaceutical, has been recognized by experts and included in the consensus by virtue of its unique advantages. In the consensus, it is clearly pointed out that patients with osteoarthritis should choose the non-steroidal anti-inflammatory drug aceclofenac, which can promote the synthesis of cartilage matrix proteoglycan, and the slow-release dosage form can be preferred, which can better control the blood concentration and improve the compliance of patients with drugs.

According to introduction, osteoarthritis is prone to occur in middle-aged and elderly people with high incidence rate. More than 50% of knee pain people over 65 years old are osteoarthritis patients, and the prevalence rate of osteoarthritis in knee pain people over 75 years old exceeds 80% . With the promotion of national centralized procurement and disease diagnosis related sub-group (DRG) payment, the price of artificial joints has dropped significantly, and doctors and the business community are faced with the choice of surgery and medication, so the launch of this consensus is timely. According to the national standardization requirements for disease treatment, both conservative treatment and drug treatment need corresponding guiding principles, which are based on guidelines and expert consensus. On the basis of being included in the expert consensus this time, Jianfeng Pharmaceutical will make every effort to carry out the promotion of the "Expert Consensus on Clinical Drug Treatment of Osteoarthritis" to further guide the safe, effective, economical and standardized use of osteoarthritis treatment drugs in clinical practice. Highlight the clinical advantages of Yueyining and better expand the market of this product.

(Xu Yuting)

More information

The company organized "charity one day donation"

On the morning of October 22, in the lobby on the first floor of Jianfeng Building, all cadres and employees of the group headquarters and subordinate enterprises working in Jianfeng Building participated in the 2021 "Charity Day Donation" activity to offer their love to Jinhua charity. In the next few days, the company's subordinate enterprises also organized "charity one-day donation" activities one after another.

2021

11-01

The company organizes new employee induction training

"Growth is more important than success. I hope everyone can become the backbone and pillars of the peak as soon as possible." On September 2, Yu Jianhong, general manager of the group company, put forward ardent hopes in the face of new employees. On the 2nd and 3rd, the group company organized induction training for new employees recruited in the past year. The group company chairman Jiang Xiaomeng, general manager Yu Jianhong and other leaders and relevant department heads gave lectures to them.

2021

09-13

Daye Peak: Typical Regional Industrial Green Development

On August 23, Huangshi Radio and Television Station broadcast the special program of "Strengthening Overall Planning and Promoting Energy Saving and Emission Reduction in Industrial Field". Daye Jianfeng Cement Company, as a typical enterprise with outstanding achievements in establishing green factories and energy saving and emission reduction in Huangshi area, appeared in the program.

2021

09-01

Yunnan Peak Helps Border Epidemic Prevention and Control

On August 22, Yunnan Peak Cement Company, through the Red Cross Society of Pu'er City and the Epidemic Prevention Headquarters of Pu'er City, donated vacuum insulation pots with a total value of 800000 yuan to the four border counties for the prevention and control of the new coronary pneumonia epidemic in the border area, and supported the prevention and control of the epidemic at the border with practical actions.

2021

09-01

Group Party Committee to Learn "July 1" Important Speech

On August 13, the party committee of the group company held a special meeting to collectively study General Secretary Xi Jinping's important speech at the celebration meeting of the 100 anniversary of the founding of the Communist Party of China, convey the requirements of the party committee at a higher level, and make arrangements for organizing party members of the company to study the "July 1" speech.

2021

08-23

Spike Ranked 2020 China's Top 100 Cement Clinker Production Capacity

Recently, the company received the "2020 China Cement Clinker Production Capacity Top 100" plaque issued by China Cement Network. The ranking of China's top 100 cement clinker production capacity is organized and evaluated by China Cement Network, an authoritative information platform for the domestic cement industry. It is released according to the actual clinker production capacity of each cement enterprise at the end of last year. The company has been ranked in the top 100 list for many consecutive years.

2021

08-23

< 1...8 9 10...61 > 跳转到页